87 articles - From Friday Jul 17 2026 to Friday Jul 24 2026
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Clin Gastroenterol Hepatol |
|---|
| New Diagnostic Criteria for Acute Severe Ulcerative Colitis in the Modern Treatment Era: A Modified Delphi Consensus by REFINED-ASUC.
This consensus provides new diagnostic criteria for ASUC in the modern therapeutic era, that can be applied to patients already in receipt of outpatient treatments. These criteria include additional clinical and laboratory parameters, for validation in prospective studies. |
| Endoscopy |
| Sedation for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) Guideline.
Main recommendations ESGE and ESGENA recommend a rational use of sedatives to reduce the environmental impact of endoscopy. Strong recommendation, moderate certainty of evidence. |
| Gut |
| International consensus on intestinal epithelial barrier assessment and therapeutic effects in inflammatory bowel diseases clinical trials.
This international consensus provides a structured framework to guide the design of future clinical trials evaluating efficacies of therapies in restoring intestinal barrier integrity and/or function in IBD. |
| J Hepatol |
| Delphi consensus in primary biliary cholangitis: Collective introspection to set a path forward. |
meta-analyses and systematic reviews
| Clin Gastroenterol Hepatol |
|---|
| Prior decompensation Identifies Patients at High Mortality Risk Despite Standard Therapy After Variceal Hemorrhage: An IPD Meta-analysis.
Among patients with Child-Pugh class A-B cirrhosis who were not candidates for preemptive TIPS and were treated with NSBBs plus EVL after VH, prior decompensation identified a subgroup at increased risk of mortality in whom the potential benefit of TIPS warrants further investigation. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
| Clinical Trial: Effectiveness and Safety of a Novel Anal Insert Device for Treatment of Faecal Incontinence.
The StaySure anal insert device is safe, well tolerated, and effective in reducing FI in patients with moderate to severe symptoms refractory to conservative therapies. |
| Clinical Trial: Multi-Strain Probiotic Improves Bile Acid Profile, Microbiome, and Metabolomic Parameters in Patients With History of Bile Acid Malabsorption-A Randomized, Controlled Trial.
The De Simone formulation probiotic induced significant microbiome and metabolome changes in patients with BAM, ultimately leading to a decrease in % faecal primary BAs and possible reduction in intestinal permeability. Clinical trials gov registration NCT #06609148, January 2, 2025. |
| Lowering the C-Reactive Protein (CRP) Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity-Matched Analysis.
NASUC is not a benign clinical entity. Colectomy risk were comparable between ASUC and NASUC inpatients when matched for objective disease severity and treatment exposure. A reduced CRP threshold (≥ 12 mg/L) improves identification of high-risk patients currently missed by the standard TWC. |
| Am J Gastroenterol |
| Absolute risk of malignancy by treatment in patients with Crohn's disease compared to the general population: a nationwide population-based cohort study.
Elevated overall cancer incidence was observed across al treatment cohorts, also in treatment-naïve patients. After exclusion of non-melanoma skin cancer, the excess cancer incidence in CD was around 1 extra case per 1,000 person-years due to lung-, small bowel -, hepatobiliary, and hematologic cancer. |
| Case-based Diagnostic Algorithms and Multidimensional Clinical Profiles for common Disorders of Gut-Brain Interaction using Rome V criteria.
Furthermore, it highlights gaps in knowledge and stimulates targeted research into these highly prevalent disorders. This case-oriented educational review will evaluate three DGBIs - functional dyspepsia, irritable bowel syndrome, and chronic abdominal pain - using the MDCP approach. |
| Characteristics and outcomes of patients with imaging-defined MASLD and histological steatosis grade S0.
"Steatosis 0" represents a potential diagnostic gray zone in MASLD. It may be caused by "burnt-out" MASLD, uneven liver fat distribution, or variability in pathological assessment. Understanding the causes and implications of "steatosis 0" is critical for diagnosis and management. |
| Colorectal cancer incidence and mortality by age group, colon location, and histology in Canada.
and relevance CRC incidence and mortality in Canada vary by age, site, and histology. In addition to a reduction in the screening start age, CRC screening programs must focus on individuals 50-54 years of age as they have not experienced a decrease in CRC incidence. |
| Disorders of Gut-Brain Interaction like symptoms in Children with Inflammatory Bowel Disease: A Multicenter Prospective Study from the Pediatric IBD Porto Group of the ESPGHAN.
DGBI-like symptoms are common in children with quiescent IBD and are associated with a substantial psychological and quality-of-life burden. |
| Oral vancomycin is not associated with meaningful changes in liver-related endpoints among adults with primary sclerosing cholangitis: A randomized, placebo-controlled trial.
OV was not associated with clinically significant reductions in markers of PSC disease severity. Impairments in quality of life may influence patient retention in clinical trials. |
| Post-Marketing Safety Signals of Microbiota-Based Live Biotherapeutic Products for Recurrent Clostridioides difficile Infection: A FAERS Pharmacovigilance Study.
FDA-approved LBPs demonstrate reassuring post-marketing safety profiles without transmitted infection signals. The extreme VOWST UTI signal is likely attributable to FDA-mandated expedited reporting obligations rather than a causal drug effect. |
| Clin Gastroenterol Hepatol |
| Automated deep learning detection of hepatic steatosis on non-contrast CT scans and discrepancy with scan reports.
We found that incidental hepatic steatosis in non-contrast CT is reported in a minority of scans. Incorporating artificial intelligence-based hepatic attenuation measurement in CT scan reading may increase reporting rates. |
| Machine Learning Prediction of Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD).
Deep learning models with ordinal-aware architectures can accurately predict liver fibrosis stages using routinely available clinical data, offering a scalable alternative to biopsy without requiring specialized biomarkers. |
| Singing Therapy versus Diaphragmatic Breathing for Supragastric Belching: A Multicenter Randomized Controlled Trial.
Singing therapy is superior to diaphragmatic breathing for supragastric belching, particularly in older patients with severe symptoms. |
| Endoscopy |
| Clinically meaningful risk factors for recurrence in T1 colorectal cancer treated with endoscopic resection alone identified by unsupervised machine learning: a multicenter study.
Three clinically distinct recurrence risk subtypes were identified in T1 CRC following ER, suggesting that morphological subclassification of T1b lesions may refine stratification beyond conventional depth-based criteria. The decision framework offers a preliminary exploratory basis for recurrence risk assessment in this population. |
| Gastroenterology |
| A DR5/Ligase 3-mediated feedback loop perpetuates immunogenicity in mismatch repair deficient colorectal cancer.
Our results reveal a functional link between dMMR and antitumor immunity, which may be useful for improving ICI therapy in tumors with different MMR statuses. |
| Gut |
| Clonal diversity underpins distinct modes of recurrence in hepatocellular carcinoma: the PLANet cohort study.
These findings show the impact of clonal structure and the tumour microenvironment on recurrence, offering insights that may help improve patient risk assessment and treatment planning. |
| Cryptogenic steatotic liver disease: a lean phenotype associated with increased liver-related mortality.
Operationally defined cryptogenic SLD accounted for a substantial proportion of lean SLD. Despite no recorded CMRFs, this phenotype was associated with liver injury markers and liver-related mortality. |
| Deciphering the prodrome of inflammatory bowel disease up to 10 years before disease onset by massively parallel serology.
Large-scale serological profiling of archived prediagnostic samples identified disease-specific immune trajectories years before IBD onset, providing novel insights into disease pathogenesis in its prodromal phase. |
| Neutrophil extracellular traps induced by tumour-derived NGAL reprogram CAF subtypes via ITGA5 to promote tumour progression in pancreatic cancer.
We define an IL-17/NGAL/NETs/ITGA5 axis linking neutrophil-derived extracellular DNA to iCAF specification and immunosuppression in PDAC. Cotargeting IL-17 and ITGA5 synergises with PD-1 blockade, providing a rationale for combinatorial immunotherapy. |
| Hepatology |
| Recompensation of decompensated cirrhosis in a spectrum of metabolic-dysfunction-related steatotic liver disease, with PEth-corroborated alcohol abstinence and modification of cardiometabolic risk factors.
PEth improved the ascertainment of alcohol exposure and phenotyping of MASLD and MetALD. Weight loss ≥10%, achievement of glycemic control, and absence of large varices were independently associated with recompensation, which occurred in 18.6% of patients with decompensated MASLD/MetALD cirrhosis. |
| J Hepatol |
| A machine learning approach to non-invasive prediction of hepatic decompensation in compensated advanced chronic liver disease: the CIRI model.
The machine-learning-based CIRI model yielded robust prognostic performance and accurate risk stratification in cACLD patients. CIRI's discrimination of decompensation risk was comparable to that of HVPG, highlighting its potential future utility to non-invasively identify "at-risk" cACLD patients. Clinical trial number NCT03267615 IMPACT AND IMPLICATIONS Hepatic decompensation marks the key clinical transition from compensated to decompensated advanced chronic liver disease and is associated with substantially worse prognosis. However, current risk assessment remains limited by the invasiveness of the gold-standard hepatic venous pressure gradient (HVPG) measurement and the infrastructure required for established non-invasive tests such as liver stiffness measurement (LSM). In this study, we developed and validated "Cirrhosis Risk Identifier" (CIRI), a machine-learning model based solely on routine laboratory and demographic data, which predicted first hepatic decompensation with performance comparable to HVPG and superior to widely used non-invasive tests including LSM, MELD and FIB-4. These findings are important for clinicians and researchers aiming to identify patients with cACLD who are at increased short-term risk of hepatic decompensation. Pending further prospective validation, CIRI could support scalable and repeatable risk stratification and help guide surveillance intensity and targeted strategies intended to prevent hepatic decompensation for high-risk patients. |
| Disruption of carbon metabolism by the hepatic mononuclear phagocytic system drives liver injury in a mouse model of severe dengue.
Fostamatinib demonstrated significant efficacy in mitigating liver injury induced by DENV infection, while concurrently alleviating inflammatory responses and ameliorating carbon metabolism disorders. Impact and implications Severe dengue, often accompanied by varying degrees of hepatic impairment, constitutes a primary cause of DENV-associated mortality. However, current specific therapeutic interventions remain inadequate. This study demonstrates that the cellular communication between the HMPS and hepatocytes is altered, thereby disrupting carbon metabolic functions in hepatocytes. The administration of fostamatinib ameliorated hepatic carbon metabolic disorders and liver injury. This provides a theoretical foundation for the development of therapeutic interventions targeting hepatic injury in severe dengue. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Editorial on 'Lowering the C-Reactive Protein (CRP) Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity-Matched Analysis'. |
| Editorial: A New Insert Device for Faecal Incontinence-To Use or Not to Use? |
| Editorial: Comparative Effectiveness in Chronic Constipation-Interpreting Real-World Evidence. |
| Clin Gastroenterol Hepatol |
| Achieving Pharmacoequity in the Treatment of Obesity: Strategies for Understanding and Tackling Disparities. |
| Blue Notes. |
| Gastroenterology |
| Serotonergic signaling in gastric physiology and motility disorders.
Recent data on naronapride, a newer 5-HT4 agonist, suggest that more selective agents may offer clinically relevant benefit while mitigating cardiovascular safety risks associated with earlier agents. By integrating molecular, physiological, and clinical data, this review aims to clarify the relevance of serotonergic signaling in gastric physiology and motility disorders, define its therapeutic applications, and identify key remaining evidence gaps. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| 10 Pearls for Clinical Practice in Disorders of Gut-Brain Interaction. |
| Sigmoid Volvulus With Concurrent Large Right Inguinal Hernia. |
| Clin Gastroenterol Hepatol |
| Chronic Liver Disease-related Mortality among Hispanic Subpopulations in the United States between 2018 and 2023. |
| Glucagon-Like Peptide-1 Receptor Agonists Are Not Associated with Increased Pulmonary Aspiration During Endoscopy and Colonoscopy. |
| MALIGNANCY RISK ASSOCIATED WITH UPADACITINIB IN IMMUNE-MEDIATED INFLAMMATORY DISEASES: A COMPARISON WITH U.S. AND GLOBAL CANCER REGISTRIES. |
| Endoscopy |
| A novel technique for biliary stent retrieval using a sphincterotome and drill dilator during balloon-assisted endoscopic retrograde cholangiopancreatography. |
| Delayed biliary hemorrhage following transjugular intrahepatic portosystemic shunt. |
| Endobiliary radiofrequency ablation for refractory cholangitis caused by mucin-producing intraductal papillary neoplasm of the bile duct. |
| Endoscopic full-thickness retrieval of a migrated plastic stent after endoscopic ultrasonography-guided liver abscess drainage. |
| Endoscopic retrieval of an impacted pancreatic duct basket using a cystotomy knife: A case report. |
| Endoscopic salvage of a N-butyl cyanoacrylate-occluded gastroscope using cholangioscopic electrohydraulic lithotripsy. |
| Endoscopic ultrasound-guided cyanoacrylate injection for gastric varices: confirming the trajectory, navigating the uncertainty. |
| Endoscopy E-Videos - recently published. |
| Generative artificial intelligence in patient education: opportunities and caution for clinical implementation. |
| Human-artificial intelligence adaptation in colonoscopy: beyond deskilling and upskilling. |
| Improving risk stratification in Barrett's esophagus - time to teach an old dog new tricks. |
| Single-balloon enteroscope-bridged endosonography-guided gallbladder drainage with lumen-apposing metal stent in Billroth II. |
| Technical determinants of successful saline-immersion vessel pre-sealing: beyond immersion alone. |
| The quest for alternative treatment strategies for acute appendicitis: How much less is "less invasive"? |
| Gastroenterology |
| Acetylcholine: A Microbial Neurotransmitter Mediating Mucosal Immunity. |
| Achieving Pharmacoequity in the Treatment of Obesity: Strategies for Understanding and Tackling Disparities. |
| An estrogen-GPR110 signaling axis drives sexual dimorphism in metabolic dysfunction associated steatotic liver disease. |
| Bepirovirsen Brings Functional Cure Closer to Reality in Chronic Hepatitis B. |
| Beyond Burnout: Recognizing and Reframing the Heartsink Response in Gastroenterologists and Hepatologists. |
| Building a Better Esophagus: Autologous Tissue Engineering Moves Closer to the Bedside. |
| From Genetic Associations to Cellular Mechanisms: Resolving IBD Risk One Cell at a Time. |
| High Prevalence of Abnormal Anthropometrics in Lean Metabolic Dysfunction-Associated Steatotic Liver Disease: A National Cross-Sectional Study. |
| The IL-10 Checkpoint in IBD - From Rare Genetics to Common Disease. |
| The many challenges of necrotizing pancreatitis. |
| Gastrointest Endosc |
| Charcoal gum-associated pseudomelanosis ilei with aluminum and titanium enrichment on elemental analysis. |
| Endoscopic closure of a persistent gastrocutaneous fistula with a laparoscopic port closure device. |
| Histology of endoscopic ultrasound-guided gastroenterostomy. |
| Unmasking Kaposi sarcoma: isolated rectal disease in a human immunodeficiency virus-negative patient. |
| What to expect beyond the gastric wall. |
| Hepatology |
| PSC's itch is worth scratching: Pruritus can be more than a symptom. |
| Pizza versus Pi*ZZ: The metabolic amplifiers in alpha-1 antitrypsin deficiency. |
| Retraction: HSP72 interacts with PRDX6 to deubiquitinate mitochondrial PINK1, activating mitophagy to treat MASLD. |
| The liver joins the CKM conversation: Fibrosis risk across the cardiometabolic spectrum. |
| The weight of progress: Why dynamic weight trajectories matter in MASLD. |
| J Hepatol |
| Redefining healthy human liver zonation using high-resolution spatial multiomics. |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Letter: Careful Interpretation of Lemborexant Efficacy and Safety in Patients With Cirrhosis. |
| Letter: Is the SCFA-Enriched Metabotype in IBS-D a Discrete Subtype or a Continuous Metabolic Gradient? |
| Letter: Low FODMAP Therapy in Paediatric Irritable Bowel Syndrome: Balancing Efficacy, Expectancy and Safety. Authors' Reply. |
| Letter: Major Adverse Outcomes in Steatotic Liver Disease Subtypes-From Etiological Classification to Biological Phenotyping. |
| Letter: Personalised FODMAP Modulation in IBS-Towards Less Restrictive Dietary Care. |
| Letter: Personalised FODMAP Modulation in IBS-Towards Less Restrictive Dietary Care. Authors' Reply. |
| Letter: Sparse Mortality Events and the Apparent OS Benefit of TDF After HCC Resection. |
| Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants. Authors' Reply. |
| Gastroenterology |
| Bismuth Quadruple Therapy as an Unstable Benchmark for Noninferiority. |
| Clarification of 'Continuous' Abdominal Pain in Rome V Diagnostic Criteria of IBS and CAPS. |
| Concerns Regarding Per-Protocol Analysis and Non-Inferiority Margin. |
| From Polypectomy Skill to Entrustment in Colonoscopy Care. |
| Gut |
| Should serotonin-noradrenaline reuptake inhibitors be considered the most effective neuromodulators for irritable bowel syndrome? |
| Time to colonoscopy after a positive faecal immunochemical test: does self-selection bias explain a null result? |